Dosimetrically determined activities in advanced differentiated thyroid carcinoma: controversies.
Authors: Finessi M, Liberini V, Deandreis D Abstract The 2013/59 EURATOM directive defines all nuclear medicine applications for therapeutic purpose as a form of radiotherapy and underlines the need of both justification and optimization of these procedures, including radioactive iodine therapy (RAIT) with [131I] for metastatic differentiated thyroid cancer (DTC), In metastatic DTC, optimal activity to be administered to achieve the best response rate with limited toxicity is still a matter of debate and international guidelines do not provide univocal recommendations on the preferable use of empiric versus a dosim...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - September 28, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Radiomics in nuclear medicine and hybrid imaging: current standings on clinical applicability.
Authors: Veit-Haibach P, El Naqa I, Visvikis D PMID: 31560184 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - September 28, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

CT radiomics and PET radiomics: ready for clinical implementation?
Authors: Bogowicz M, Vuong D, Huellner MW, Pavic M, Andratschke N, Gabrys HS, Guckenberger M, Tanadini-Lang S Abstract Today, rapid technical and clinical developments result in an increasing number of treatment options for oncological diseases. Thus, decision support systems are needed to offer the right treatment to the right patient. Imaging biomarkers hold great promise in patient-individual treatment guidance. Routinely performed for diagnosis and staging, imaging datasets are excepted to hold more information than used in the clinical practice. Radiomics describes the extraction of a large number of meaningfu...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - September 20, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Are radiomics ready for clinical prime-time in PET/CT imaging?
Authors: Cheze Le Rest C, Hustinx R Abstract Over the last few years the field of radiomics has been gaining ground in the field of nuclear medicine and in multimodality imaging. Within this context, numerous studies have exploited the potential interest of radiomics in clinical practice, within the diagnostic field as well as in prognostic and predictive modeling of patient response. Although these studies have showed some interesting results, there are also persistent conflicting conclusions. Most of these studies suffer from consistently low number of patients, lack of external dataset based validation of most f...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - September 20, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Machine learning for radiomics-based multi-modality and multi-parametric modeling.
Authors: Wei L, Osman S, Hatt M, El Naqa I Abstract Due to the recent developments of both hardware and software technologies, multimodality medical imaging techniques have been increasingly applied in clinical practice and research studies. Previously, the application of multimodality imaging in oncology has been mainly related to combining anatomical and functional imaging to improve diagnostic specificity and/or target definition, such as positron emission tomography/computed tomography (PET/CT) and single-photon emission computed tomography (SPECT)/CT. More recently, the fusion of various images, such as multi-...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - September 20, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Integrating radiomics into clinical trial design.
Authors: Waninger JJ, Green M, Cheze Le Rest C, Rosen B, El Naqa I Abstract In radiomics, quantitative features that describe phenotypic tumor characteristics are derived from radiographic images. Because radiomics generates information from routine medical images, it is a powerful way to non-invasively examine the spatial and temporal heterogeneity of disease, and thus has potential to significantly impact clinical trial design, execution, and ultimately patient care. The aim of this review article is to discuss how radiomics may address some of the current challenges in clinical randomized control trials, and the...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - September 20, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Role of intravoxel incoherent motion parameters in gastro-esophageal cancer: relationship with 18F-FDG-PET, CT perfusion and MR perfusion imaging parameters.
This study evaluated the relationship of multimodality parameters derived from intravoxel incoherent motion method (IVIM), 18F- FDG-PET, CT perfusion and dynamic contrast enhanced MRI in patients with gastro- esophageal cancer and investigated their histopathological correlation. METHODS: Thirty-one consecutive patients (28 male; median age 63.9 years; range 37-84 years) with gastro-esophageal adenocarcinoma (n=22) and esophageal squamous cell carcinoma (n=9) were analyzed. IVIM parameters: pseudodiffusion (D*), perfusion fraction (fp), true diffusion (D) and the threshold b-value (bval); PET-parameters: SUVmax, metabo...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - September 11, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

PET imaging of Dopamine Transporter with [18F]LBT-999: initial evaluation in healthy volunteers.
CONCLUSIONS: These findings support the usefulness of [18F]LBT-999 for a quantitative clinical evaluation of presynaptic dopaminergic innervation. PMID: 31496203 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - September 11, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Evaluation of quantitative imaging parameters in head and neck squamous cell carcinoma.
CONCLUSIONS: Functional imaging represents an attractive and non-invasive modality to assess complex biological phenomena in solid tumors. Larger tumor volume and increasing hypoxia emerged as putative prognostic imaging biomarkers in HNSCC. PMID: 31496204 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - September 11, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Sterility assurance of technetium-99m radiopharmaceuticals: no specific air conditions are required for their preparation, storage and dispensation.
CONCLUSIONS: This study strongly supports that it is not necessary any special ambient air conditions to prepare, store and dispense extemporaneous technetium-99m radiopharmaceuticals in order to preserve their sterility when the basic aseptic rules for closed procedures are followed. PMID: 31359743 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - August 1, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

PSMA uptake on [68Ga]-PSMA-11-PET/CT positively corrects with prostate cancer aggressiveness.
This study is to validate the relationship between SUVs with prostate cancer (PCa) aggressiveness and its role in evaluation of clinically significant PCa (csPCa) and risk stratification. METHODS: We retrospectively enrolled 51 patients who underwent [68Ga]-PSMA PET/CT (PET/CT) before radical prostatectomy (RP). PET/CT results were corrected with whole mount histology. The relationship between SUVs and aggressiveness related indictors including Gleason score, T stage, initial PSA and tumor size were analyzed. The cutoff value for detection of overall PCa, csPCa and intermediate/high-risk PCa were calculated by receiver...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - August 1, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Radioiodine dosimetry in advanced thyroid cancer.
Authors: Giovanella L, Lassmann M Abstract PMID: 31333007 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 25, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Physics aspects of setting up a multi-centre clinical trial involving internal dosimetry of radioiodine treatment of differentiated thyroid cancer.
Authors: Taprogge J, Leek F, Flux GD Abstract The field of molecular radiotherapy is expanding rapidly, with the advent of many new radiotherapeutics for the treatment of common as well as for rare cancers. Treatment outcome is dependent on the absorbed doses delivered to target volumes and to healthy organs-at-risk, which are shown to vary widely from fixed administrations of activity. There have been significant developments in quantitative imaging and internal dosimetry in recent years, although clinical implementation of these methods has been slow in comparison with external beam radiotherapy, partly due to th...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 19, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Molecular imaging of bone metastases using tumor-targeted tracers.
Authors: Karamzade-Ziarati N, Manafi-Farid R, Ataeinia B, Langsteger W, Pirich C, Mottaghy FM, Beheshti M Abstract Bone metastasis is a disastrous manifestation of most malignancies, especially in breast, prostate and lung cancers. Since asymptomatic bone metastases are not uncommon, early detection, precise assessment, and localization of them are very important. Various imaging modalities have been employed in the setting of diagnosis of bone metastasis, from plain radiography and bone scintigraphy to SPECT, SPECT/CT, PET/CT, MRI. However, each modality showed its own limitation providing accurate diagnostic perf...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 19, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Radionuclide imaging and therapy of bone metastases in the era of targeted therapy.
Authors: van den Wyngaert T, Paycha F Abstract PMID: 31315348 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 19, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer.
Authors: Weber M, Binse I, Nagarajah J, Bockisch A, Herrmann K, Jentzen W Abstract Radioiodine therapy of thyroid cancer was the first successful radionuclide therapy in the treatments of cancer, although its clinical use is empirical and not based on precise dosimetry. 124I is a positron- emitting radionuclide and positron emission tomography/computed tomography (PET/CT) with 124I currently provides the most accurate estimation of the absorbed (radiation) dose to thyroid cancer lesions. In the application, serial 124I PET/CT scans are performed to determine the time uptake curves and to delineate the volumes of th...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 13, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Bone metastases in the era of targeted treatments: insights from molecular biology.
Authors: Dewulf J, Vangestel C, Verhoeven Y, van Dam P, Elvas F, van den Wyngaert T, Clézardin P Abstract Bone metastases remain a common feature of advanced cancers and are associated with significant morbidity and mortality. Recent research has identified promising novel treatment targets to improve current treatment strategies for bone metastatic disease. This review summarizes the well-known and recently discovered molecular biology pathways in bone that govern normal physiological remodelling or drive the pathophysiological changes observed when bone metastases are present. In the rapidly changing world...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 13, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Quantitative radionuclide imaging of bone metastases.
Authors: De Schepper S, Ritt P, van den Wyngaert T, Kuwert T Abstract By improving the localization of foci of pathological tracer uptake and offering information on their CT morphology, SPECT/CT hybrid imaging has considerably improved the diagnostic accuracy of skeletal scintigraphy. SPECT/CT also has the potential to measure tracer uptake in vivo in absolute units. The present article reviews the methodology for and the potential clinical impact of quantitative skeletal scintigraphy. PMID: 31298016 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 13, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

The changing role of radium-223 in mCRPC: has the European Medicines Agency missed the mark with revising the label?
Authors: van den Wyngaert T, Tombal B Abstract Radium-223 is a life prolonging treatment in symptomatic men with metastatic castrate resistant prostate cancer (mCRPC) and bone metastases, but no visceral disease, regardless of prior treatment with docetaxel. Together with four other drugs (i.e. abiraterone, cabazitaxel, docetaxel, enzalutamide), it has been available for clinical use since 2013 and has been shown to also provide benefits in quality-of-life and societal benefits. However, in 2018 the European Medicines Agency (EMA) ruled to restrict the use of radium-223 to a more advanced disease setting after at l...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 13, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Response assessment of bone metastatic disease: seeing the forest for the trees - RECIST, PERCIST, iRECIST, and PCWG-2.
Authors: Castello A, Lopci E Abstract Tumor response is often used as a surrogate marker for survival practically in all clinical trials. Therefore robust and valid response criteria during the course of trials are fundamental for the assessment of response to therapy. This aspect, however, becomes particularly challenging when it comes to bone metastases. In the era of targeted therapies and immune-checkpoint inhibitors (ICI), response assessment by morphologic-based criteria cannot detect the real tumor response and, consequently, fail to demonstrate the actual clinical benefit. This review will focus on some of ...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 11, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Molecular imaging of bone metastases using bone targeted tracers.
Authors: Vaz S, Sharjeel U, Gnanasegaran G, Paycha F, van der Wyngaert T Abstract Molecular imaging using bone targeted tracers has been used in clinical practice for almost fifty years and still plays an essential role in the diagnosis and follow-up of bone metastases. It includes both [99mTc]bisphosphonates for bone scan and [18F]NaF for PET/CT which are very sensitive to detect osteoblastic activity, but it is important to consider several aspects to increase the specificity of reported findings (such as specific tracer characteristics and mechanism of action, patient's clinical history, common metastatic patter...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 11, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Optimal use of [18F]FDG-PET/CT in patients with fever or inflammation of unknown origin.
CONCLUSIONS: [18F]FDG-PET/CT contributed to the final diagnosis in 45.2% of patients, but never contributed when both inflammatory parameters and body temperature were normal. Repeat [18F]FDG-PET/CT should only be performed in patients with a non- contributory [18F]FDG-PET/CT when new symptoms or signs appear, or when the first scan was made in absence of fever or elevated inflammatory parameters. PMID: 31271266 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 6, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

[18F]fluorodeoxyglucose-positron emission tomography and glucose-transporter type 1 (GLUT-1) expression in untreated primary small bowel adenocarcinoma.
CONCLUSIONS: Primary small bowel adenocarcinomas have a high GLUT-1 expression. Tumor lesions consistently demonstrated high FDG uptake pre-treatment, suggesting FDG-PET utility in staging and follow-up of these tumors. PMID: 31271267 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 6, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Prognostic value of metabolic parameters on baseline 18F-FDG PET/CT in small cell lung cancer.
In this study, 38 consecutive SCLC patients (34M, 4F, age:65.76 8.18 years) who were referred to 18F-FDG PET/CT for staging between October 2006-January 2011 were included. SUVmax, SUVmean, SUVpeak, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were calculated. Overall survival (OS) was calculated from the date of the initial PET/CT to death from any cause. Survival tables were obtained and Kaplan Meier curves were recunstructed. Mantel- Cox regression analysis was performed in order to invesitgate if any of these parameters have an effect on survival along with other clinical risk factors. RESULTS...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 6, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Leveraging the power of non-radium radionuclide treatments in bone metastases.
Authors: Thapa P, Basu S Abstract This review overviews the current status and clinical results of unsealed radionuclide therapies in skeletal metastasis. The other modes of treatment such as external bean radiotherapy and the newer receptor targeted radiopharmaceuticals tagged to alpha and beta particle emitting radionuclides have also been touched upon. With the advent of the latter in recent years, the intravenously administered radiopharmaceuticals that can be employed in the setting of skeletal metastases can be broadly categorized into (i) bone-seeking and (ii) receptor targeted specific tumor-seeking radioph...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 6, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Radioiodine therapy of advanced DTC: clinical considerations and multidisciplinary approach.
Authors: Giovanella L, Scappaticcio L Abstract Differentiated thyroid cancer (DTC) accounts for 95% of all thyroid cancers and is generally an indolent tumor, treated effectively with surgery, radioactive iodine, and thyroid-stimulating hormone suppressive therapy. However, 5-10% of patients have advanced disease, with aerodigestive tract invasion, distant metastases, or radioiodine refractory disease, with poor prognosis. This review focuses on the approaches for treating advanced DTC, including management of gross extra-thyroidal extension, recurrent loco-regional or distant metastatic disease, the role of extern...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 6, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Advanced differentiated thyroid cancer: when to stop radioiodine?
Authors: Giovanella L, van Nostrand D Abstract Radioiodine (RAI) is a pivotal important treatment for patients with metastatic differentiated thyroid cancer (DTC). In order to determine when a patient will no longer respond to RAI, multiple classifications have been described to categorize a patient as radioiodine refractory (RAI-R). Current classifications, although very useful, are problematic and controversial and cannot be merely applied in the context of individualized patient management. In addition, classifications on how to define RAI-R disease are continuosly evolving as more studies are published and mana...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 6, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

The case for dosimetry in I-131 therapy of differentiated thyroid carcinoma.
Authors: Verburg FA Abstract For advanced DTC several I-131 activity selection strategies are available 1-5. The most commonly practised approach concerns the empirical activity selection, in which the physician chooses an activity based on convention, experience and patient related parameters. The second available strategy is to perform lesion dosimetry. In this case, the activity to be administered is determined after a pretherapeutic dosimetric assessment to calculate the minimal activity required to achieve an effective absorbed dose or a maximum safe activity based on the delivered blood /bone marrow absorbed ...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 6, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Is 99mTc-HMPAO-leukocyte imaging an accurate method in evaluating therapy result in prosthetic joint infection and diagnosing suspected chronic prosthetic joint infection?
CONCLUSIONS: 99mTc-HMPAO-leukocyte imaging appears to be an accurate method to diagnose or exclude chronic PJI, but cannot be recommended for therapy evaluation of PJI in patients with on-going antibiotic treatment. PMID: 31140233 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - May 30, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Differential diagnostic ability of 18F-FDG PET/CT radiomics features between renal cell carcinoma and renal lymphoma.
Authors: Zhu S, Xu H, Shen C, Wang Y, Xu W, Duan S, Chen H, Ou X, Chen L, Ma X Abstract BACKGROUND: To determine the differential diagnostic value of texture parameters of PET/CT on renal cell carcinoma and renal lymphoma. METHODS: Twenty renal lymphoma and 18 renal cell carcinoma (RCC) patients were analyzed in this study. The pathological information and basic characteristics were extracted from the electronic medical record system of our hospital. We used LIFEx package to extract data from the radiomics images. Receiver operating characteristic analysis and binary logistic regression analysis was applied in ...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - May 30, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Improved automated synthesis of (2-((2-6-[18F]fluoro-5-(methylamino) pyridin-2-yl)benzothiazol-6-yl)thio)ethanol ([18F]FINH-Me) via direct radio-fluorination and quality control for A β-amyloid imaging.
CONCLUSIONS: [18F]FINH-Me is a promising PET probe to be used in AD diagnose. PMID: 31140235 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - May 30, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Comparison of visual criteria for amyloid-PET reading: could their merging reduce the inter-raters variability?
Authors: Paghera B, Altomare D, Peli A, Morbelli S, Buschiazzo A, Bauckneht M, Giubbini R, Rodella C, Camoni L, Boccardi M, Festari C, Muscio C, Padovani A, Frisoni GB, Guerra UP Abstract BACKGROUND: Three different amyloid tracers labeled with 18-flourine have been introduced into clinical use. The leaflets of tracers indicate different visual criteria for PET reporting. In clinical practice, it isn't yet ascertained whether this criteria are equivalent in terms of diagnostic accuracy or if anyone is better than another. We aimed to evaluate the inter and intra-rater variability of visual assessment of 18F-Florbet...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - May 17, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

18F-FDG-PET/CT imaging of uterine cervical cancer recurrence in women with and without HIV infection.
Authors: Lawal IO, Ololade KO, Popoola GO, Ankrah AO, Vorster M, Maes A, Mokgoro NP, van de Wiele C, Sathekge MM Abstract BACKGROUND: To compare the rate, time and, pattern of recurrence of cervical cancer between patients with and without HIV infection and to determine factors predicting cervical cancer recurrence in patients evaluated by 18F-FDG-PET/CT. METHODS: We reviewed the 18F-FDG-PET/CT images of patients with histologically proven cervical carcinoma who were presenting with suspected recurrence. We extracted epidemiologic data, previous treatment, histologic subtype, HIV status, viral load and CD4 coun...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - May 17, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Two-way crossed cerebellar diaschisis in a clinically isolated syndrome suggestive of multiple sclerosis.
Authors: Boffa G, Lapucci C, Morbelli SD, Nobili FM Abstract The term diaschisis refers to a neural dysfunction manifesting in anatomically intact, but functionally related, brain regions distant from a primary lesion. Here we report the diaschisis phenomenon as a consequence of a first demyelinating event in the middle and superior cerebellar peduncles in both the ipsilateral cerebellar hemisphere and in the contralateral thalamus and cerebral cortex (two-way crossed cerebellar diaschisis), resulting in the simultaneous disruption of the afferent cortico-ponto- cerebellar pathway and the efferent cerebellar-thalam...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - May 17, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Prognostic value and optimal threshold of first thyroglobulin in low/intermediate risk DTC.
Authors: Zakavi SR, Ayati N, Zare S, Ayati A, Sadri K, Fekri N, Abbasi B, Shafiei S Abstract BACKGROUND: The aim of this study was to define prognostic value and optimal threshold of first thyroglobulin (fTg) measured after thyroidectomy and just before radio-iodine therapy (RIT), in low/intermediate risk patients with differentiated thyroid cancer (DTC). MATERIALS: This is a retrospective study in 383 patients with DTC who were treated with surgery followed by RIT. Response to treatment was assessed 1 and 2 years after RIT. Odds ratio of different risk factors like age, sex, TNM stage, fTg and Anti-Tg Ab were ...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - March 28, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Diagnostic value of PET textural indices for malignancy of FDG-avid adrenal lesions.
Authors: Thuillier P, Bourhis D, Schick U, Alavi Z, Guezennec C, Robin P, Kerlan V, Salaun PY, Abgral R Abstract BACKGROUND: PET Textural indices could have an add-on diagnostic value for diagnosis of malignancy in patients with FDG-avid adrenal lesions. METHODS: Consecutive patients referred for a FDG-PET/CT to our nuclear medicine department from June 2012 to June 2017 were retrospectively screened. Inclusion criteria were: patients with a FDG-avid adrenal lesion (uptake≥liver background); malignant/benign lesion confirmed histologically or with follow-up imaging examination. Pheochromocytomas were not inc...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - March 28, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
Authors: Hu WD, Wang HC, Wang YB, Cui LL, Chen XH Abstract BACKGROUND: 18F-FDG PET/CT metabolic characteristics provide the crucial biologic and molecular information for tumors. To explore the relationships between 18F-FDG PET/CT derived parameters such as maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG) of primary tumor and clinical stage in different histopathologic subtypes of lung cancer. METHODS: A total of 97 newly diagnosed lung cancer patients (69 males, 28 females; average age 65.1 years) with pathologically proven were retrospectively analyzed, w...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - March 28, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Granulocyte radiolabelling using Leukokit ® with introduction of a density gradient medium as ancillary material.
CONCLUSIONS: Purification of granulocytes with Leukokit® can safely, easily and effectively be performed using a density gradient medium. Moreover, clarification regarding the status of density gradient medium could provide support for its clinical use even if further studies are needed. Since all technical obstacles have been removed, the precautionary principle should apply and lead users to eliminate lymphocytes that are highly radiosensitive cells and whose in vivo fate is uncertain. PMID: 30792379 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 24, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Comparison of different motion correction techniques for dynamic FDG-PET/CT studies in breast cancer patients.
CONCLUSIONS: Both applied methods proved to be reproducible and reliable, especially Method II, where every measured kinetic parameter showed excellent interrater reliability. Different approaches of motion correction could have a significant effect on the results of the kinetic modelling; therefore careful selection of the most reliable method is advised. PMID: 30792380 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 24, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Baseline PET as prognostic index in diffuse large B-cell lymphoma and grade IIIb follicular lymphoma: a retrospective study of a single-centre experience.
CONCLUSIONS: The results of our study suggest that MTV could be a useful tool to predict response to R-CHOP in patients affected with DLBCL and FL grade 3b and that a multi-parameters evaluation should be considered. PMID: 30781938 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 21, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Is 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography useful to discriminate metachronous lung cancer from metastasis in patients with oncological history?
CONCLUSIONS: In oncological patients, despite its high detection rate, 18F-FDG PET/CT, as well as any other clinico-anatomical features, cannot distinguish whether a malignant solitary pulmonary nodule is a metachronous lung cancer or a metastasis, supporting the need of histological differential diagnosis. PMID: 30654605 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - January 19, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

PSMA radioligand therapy of prostate cancer.
Authors: Beheshti M, Heinzel A, von Mallek D, Filss C, Mottaghy FM Abstract Defining an optimal therapeutic approach in metastatic castration-resistance prostate cancer (mCRPC) patients in advanced stages is still challenging in routine clinical practice. Prostate- specific membrane antigen (PSMA) targeted radionuclide therapy with β- or α-emitters such as 177-Lutethium (177Lu) or 225-Actinium (225A) has been a main focus at multiple academic researche centers in the last few years. This review article provides an overview of PSMA characteristics, clinical performance, safety and toxicity of PSMA targete...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - January 16, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Impact of functional imaging in prostate cancer: a clinical point of view.
Authors: Nicolotti DG, Finessi M, Guarneri A, Pilati E, Giunta F, Deandreis D Abstract PMID: 30644307 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - January 16, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Molecular PET imaging in adaptive radiotherapy: brain.
CONCLUSIONS: The adaptation of treatment volumes during RT (ART) seems promising, but its development requires improvements in several areas and an interdisciplinary approach involving radiology, nuclear medicine and radiotherapy. We review the literature on biological imaging to outline the perspectives for using DPRT and ART in brain tumors. PMID: 30497232 [PubMed - in process] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - December 2, 2018 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Role of PET imaging in adaptive radiotherapy for lymphoma.
This article will discuss the role of PET in selecting patients for radiotherapy, its influence on the choice of target volume and radiotherapy dose and the practicalities of how PET/CT scanning is incorporated into the radiotherapy planning process. PMID: 30497233 [PubMed - in process] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - December 2, 2018 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Predictive factors determining incomplete response to radioiodine therapy in patients with differentiated thyroid cancer.
Authors: Szczepanek-Parulska E, Wojewoda-Korbelak M, Borowczyk M, Kaluzna M, Brominska B, Ziemnicka K, Czepczynski R, Baczyk M, Ruchala M Abstract BACKGROUND: Although differentiated thyroid cancer (DTC) has relatively favorable course, factors predicting the course of the disease are intensively searched. The aim of the study was to identify the clinical factors determining incomplete response to radioiodine therapy in patients with differentiated thyroid cancer. METHODS: We retrospectively analyzed 385 consecutive patients with DTC treated and followed-up at a single tertiary reference center. We investigated...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - September 19, 2018 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Evaluation of physiologic and abnormal glucose uptake in palatine tonsils: differential diagnostics with sequential dual-time-point 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography examinations.
Authors: Pietrzak AK, Kazmierska J, Marszalek A, Cholewinski W Abstract BACKGROUND: The aim of this article was to evaluate the usefulness of sequential dual- time-point 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography (DTP [18F]FDG PET/CT) in distinguishing physiologic, inflammatory and malignant palatine tonsils as difficult to differentiate in the oncological practice. METHODS: A total of 90 patients before the treatment underwent sequential DTP [18F]FDG PET/CT examinations. We analyzed 104 structures in 90 patients: 31 physiologic tonsils, 28 histopathologically confirmed inf...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - September 19, 2018 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Comparison of post-therapeutic sequential 131I whole-body scans in the detection of metastatic thyroid cancer.
Authors: Qui L, Tan H, Yin H, Zhou J, Cheng D, Shi H Abstract BACKGROUND: The aim was to compare the detect ability of 3 sequential 131I whole-body scans (tri-WBS) on the second, third, and fourth day after 131I therapy for metastatic thyroid cancer. METHODS: Differentiated thyroid cancer patients who received oral high-dose 131I therapy underwent routinely tri-WBS on the second, third, and fourth day after total or near-total thyroidectomy in our hospital. We enrolled 137 patients with 261 tri-WBSs in this study between January 2015 and November 2017. The inclusion criteria was that at least one metastasis was...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - September 19, 2018 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Correlation of 18F-FDG uptake and thyroid cancer stem cells.
CONCLUSIONS: The pre-therapeutic tumor SUVmax obtained from 18F-FDG PET/CT may be a potential predictor for evaluating the proportion of CSC population in individual patients with TC. PMID: 30160089 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - August 31, 2018 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Applicability of sentinel lymph node biopsy in papillary thyroid cancer.
CONCLUSIONS: Our results support that SLN biopsy by SPECT/CT along with intraoperatory image techniques is applicable in early stages of PTC (cT1-2, cN0), allowing to avoid unnecessary PL. PMID: 29999291 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 14, 2018 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research